Lungpacer Medical, Inc. — SEC Form D Filing

Lungpacer Medical, Inc. filed an SEC Form D on April 28, 2026, reporting $12.00M raised in Healthcare Technology.

Form D filing details

Filing
SEC Form D
Filing date
April 28, 2026
Amount reported
$12.00M
Round stage
Series A
Industry
Healthcare Technology
Website
https://lungpacer.com/

What the company does

Securities: Debt, Unsecured Convertible Promissory Notes. Exemption: Rule 506(b). Incorporated: BRITISH COLUMBIA, CANADA

Problem

Mechanical ventilation can result in prolonged dependencies and increased risks such as reintubation and tracheostomy, and patients need effective solutions for quicker weaning and restoration of independent breathing.

Solution

The Lungpacer AeroPace System uses a temporary transvenous diaphragm neurostimulation approach to stimulate the phrenic nerves, promoting faster weaning from mechanical ventilation and reducing associated risks.

Why now

As healthcare systems strive to reduce the duration of mechanical ventilation and associated complications, Lungpacer offers a timely solution that aligns with these goals.

Verdict

Investors approved this funding round because Lungpacer tightly aligned its narrative with urgent healthcare needs, not simply by presenting a new technology. They implicitly bet on the increasing pressure on healthcare providers to innovate in patient care, specifically regarding mechanical ventilation. However, the potential for limited upside stems from the crowded landscape of established players who have resources to quickly adapt or replicate solutions, undermining durability in the face of competition.

Source: SEC EDGAR Form D filing